Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1320

Shown on this page

Current sort

Live official records

Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 32
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 27 more

Conditions: Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Seminoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Interventions: Best Practice, Biopsy Procedure, Biospecimen Collection, Bleomycin Sulfate, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Pulmonary Function Test, Questionnaire Administration; Other · Procedure · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 1,780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 566
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 338 more

Conditions: Diabetes
Interventions: Gut motility quantification using a capsule after initiating GLP-1RA therapy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection; Procedure
Lead sponsor: PedAL BCU, LLC; Other
Eligibility: Up to 22 Years
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 164
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more

Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma
Interventions: Biospecimen Collection, Computed Tomography, Questionnaire Administration, Thoracoscopy, Thoracotomy; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 220
States / cities: Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 142 more

Conditions: Ventral Hernia
Interventions: AGN-151607-DP, Placebo for AGN-151607-DP; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Riverside, California • Jacksonville, Florida • Miami, Florida + 10 more

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: TARA-002; Biological
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 44
States / cities: Homewood, Alabama • Phoenix, Arizona • Queen Creek, Arizona + 38 more

Conditions: Rupture of Anterior Cruciate Ligament
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 1,234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 47
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 39 more

Conditions: Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Interventions: VAX014, Nivolumab or pembrolizumab; Drug · Combination Product
Lead sponsor: Vaxiion Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 4 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 100
States / cities: Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more

Conditions: Choline Deficiency, Liver Injury
Interventions: Choline Chloride for Injection, Placebo; Drug
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Aurora, Colorado • Miami Lakes, Florida • Chicago, Illinois + 5 more

Conditions: Rupture of Anterior Cruciate Ligament
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 10 Years to 80 Years
Enrollment: 3,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2028
U.S. locations: 8
States / cities: Boulder, Colorado • Iowa City, Iowa • St Louis, Missouri + 5 more

About this Cleveland Clinic institution page

What this page lists: ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Cleveland Clinic

Filter and sort this campus

Live official records

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Multicenter ACL Revision Study (MARS)

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support

Multicenter Orthopaedics Outcomes Network for ACL Reconstructions

About this Cleveland Clinic institution page